Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Matthew Dube

Emergency Medical Services Evanston, IL Medical Doctor

NPI 1710125976 CMS profile 469136

2650 Ridge Ave, Evanston, IL 60201

Open in the dashboard

General payments

$63

3 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Dube of Evanston, IL is reported in the CMS Open Payments database as having received $63 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Emergency Medical Services profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46 2
2023 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Dube
  • Emergency Medical Services median
  • Middle half of Emergency Medical Services
  • National median

In program year 2025, general payments to Matthew Dube were reported at $46. Among 443 Emergency Medical Services profiles paid that year, the median was $72 and the middle half received between $25 and $169.

Show as a table
Year Matthew Dube Emergency Medical Services median Middle half National median
2019 $0 $62 $20–$162 $163
2020 $0 $37 $17–$119 $114
2021 $0 $58 $20–$133 $132
2022 $0 $61 $21–$156 $149
2023 $17 $58 $21–$173 $160
2024 $0 $62 $24–$161 $164
2025 $46 $72 $25–$169 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Argenx US, Inc. $24 1 payment
  2. Lundbeck LLC $22 1 payment
  3. Pacira Pharmaceuticals Incorporated $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $63 3 payments
Products named General payments · program years 2023–2025
  1. VYVGART Hytrulo $24 1 payment
  2. VYEPTI $22 1 payment
  3. Exparel $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

81

Median for Emergency Medicine: 88

Drug cost

$502

Median for Emergency Medicine: $590

Branded share of claims

37%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 16 $231
Cephalexin Generic 12 $78
Ondansetron Odt Ondansetron Brand 15 $63
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $55
Meclizine Hcl Generic 11 $46
Tramadol Hcl Generic 12 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$935,313

Of which drugs: $789,310

Medicare patients

979

Average age 78

Services billed

104,281

639 women, 340 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Osteoporosis 39%
Chronic kidney disease 32%
Depression 32%
Diabetes 31%
Ischemic heart disease 31%
Heart failure 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 118 8,700 $183,715
Injection, romosozumab-aqqg, 1 mg J3111 Office 19 18,270 $159,311
Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medica Q0224 Office 12 19 $122,585
Injection, zoledronic acid, 1 mg J3489 Office 56 280 $1,342
Infusion, normal saline solution, 250 cc J7050 Office 79 158 $82

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medical Services in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record